MINIATURIZED CRISPR PACKS A MIGHTY GENE EDITING PUNCH

Summary from the TLDR newsletter

One of the biggest issues with CRISPR-Cas9 is that the system is too large, making it difficult to deliver the gene editor. Mammoth Biosciences' NanoCas is a version of the CRISPR-Cas9 system that is roughly one-third the size of the original, allowing the tool to be used for gene therapy inside muscles, the brain, the heart, and other tissues. The team is already exploring the system's potential for targeting brain diseases. The technology could be modified for use in epigenetic or base editing.